Table 4.
Recommended dosages of dexmedetomidine, tiletamine-zolazepam, and butorphanol. Dosages recommended for use were determined based on anesthetic duration, induction, and recovery time, as well as safety, as measured by mortality. Increased dosages of dexmedetomidine and tiletamine-zolazepam resulted in an increasing trend of anesthetic duration and recovery times. Dexmedetomidine and tiletamine-zolazepam were administered IP and butorphanol was administered in all above listed trials at 3 mg/kg SC. Data are reported in predicted marginal means and standard error.
| Anesthetic duration (minutes) | Recovery time (minutes) |
Anesthesia achieved (%) | Heart rate (bpm) | Respiratory rate (bpm) | |
|---|---|---|---|---|---|
| Dexmedetomidine 0.2 mg/kg | |||||
| Tiletamine-zolazepam 20 mg/kg | 73 (±16) | 168 (±16) | 100% (6/6) | 191 (±12) | 137 (±4) |
| Tiletamine-zolazepam 40 mg/kg | 143 (±16) | 217 (±16) | 100% (6/6) | 198 (±12) | 137 (±4) |
|
| |||||
| Dexmedetomidine 0.4 mg/kg | |||||
| Tiletamine-zolazepam 20 mg/kg | 110 (±16) | 224 (±16) | 100% (6/6) | 202 (±12) | 134 (±4) |
| Tiletamine-zolazepam 40 mg/kg | 163 (±16) | 273 (±16) | 100% (6/6) | 209 (±12) | 134 (±4) |